- * At the time of informed consent:
- * 18 years of age (adults); or
- * 12 to less than (\<) 18 years of age (adolescents, where approved and when enrollment for adolescents has been opened by the sponsor, with the endorsement of the Independent Data Monitoring Committee \[IDMC\])
- * Diagnosed with SCD (any genotype).
- * Presented at the study site with a new acute VOC necessitating treatment with parenteral opioids.
Sickle Cell Disease
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 | PHASE 2 | INTERVENTIONAL
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Univ. of California, San Francisco Health Care
Oakland,California,United States,94609
University of California Irvine
Orange,California,United States,92868
Golisano Children's Hospital
Fort Myers,Florida,United States,33908
The Foundation for Sickle Cell Disease
Hollywood,Florida,United States,33023
University of Maryland
Baltimore,Maryland,United States,21201
Detroit Medical Center
Detroit,Michigan,United States,48201
Henry Ford Health System
Detroit,Michigan,United States,48202
Mount Sinai Medical Center
New York,New York,United States,10029
Jacobi Medical Center
The Bronx,New York,United States,10461
University of Cincinnati
Cincinnati,Ohio,United States,45267
The Ohio State University
Columbus,Ohio,United States,43085
University of Pittsburgh
Pittsburgh,Pennsylvania,United States,15224
Hillman Cancer Center
Pittsburgh,Pennsylvania,United States,15232
Virginia Commonwealth University
Richmond,Virginia,United States,23298
Hacettepe Universitesi
Ankara,Virginia,Turkey (Türkiye),06230
Istanbul Universitesi
Istanbul,Virginia,Turkey (Türkiye),34093
zel Acibadem Adana Hastanesi
Seyhan,Virginia,Turkey (Türkiye),01130
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov